Edition:
United Kingdom

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.SS)

600196.SS on Shanghai Stock Exchange

39.73CNY
20 Jul 2018
Change (% chg)

¥-0.21 (-0.53%)
Prev Close
¥39.94
Open
¥39.90
Day's High
¥39.90
Day's Low
¥39.00
Volume
18,413,481
Avg. Vol
23,821,959
52-wk High
¥48.28
52-wk Low
¥28.15

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharmaceutical Group Announces Placing Of H Shares Under General Mandate
Thursday, 19 Jul 2018 

July 19 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::ANNOUNCES PLACING OF H SHARES UNDER GENERAL MANDATE.NET PROCEEDS OF PLACING WILL BE ABOUT HK$2,578.07 MILLION.PLACING SHARES COMPRISE 68 MILLION H SHARES TO BE ALLOTTED AND ISSUED BY CO.PLACING SHARES AT PLACING PRICE OF HK$38.20 PER H SHARE.  Full Article

Shanghai Fosun Pharmaceutical's Unit To Invest About $106 Mln In Butterfly Network Inc
Friday, 13 Jul 2018 

July 13 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT TO INVEST ABOUT $106 MILLION IN BUTTERFLY NETWORK INC.  Full Article

Shanghai Fosun Pharmaceutical Group unit receives approval for drug clinical trial
Thursday, 12 Jul 2018 

July 12(Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says its Jiangsu-based biomedical unit received approval for drug clinical trial for a kind of tablet, from China Food and Drug Administration.  Full Article

Shanghai Fosun Pharmaceutical Group Says Fosun High Tech Acquired 2 Mln H Shares Of Co
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::FOSUN HIGH TECH ACQUIRED 2 MILLION H SHARES OF CO AT AVERAGE PURCHASE PRICE OF HK$40.15 PER H SHARE.DEAL FOR TOTAL PURCHASE PRICE OF RMB68.23 MILLION.  Full Article

Shanghai Fosun Pharmaceutical Group unit receives GMP certificate
Wednesday, 27 Jun 2018 

June 27(Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says unit received goods manufacture practice (GMP) certificate from Sichuan Food and Drug Administration.Certificate issued to powder-injection manufactured by the unit and the valid period is until May 20, 2023.  Full Article

Shanghai Fosun Pharma's Unit Agrees To Buy 28 Pct Stake In Medical Equipment Firm For 406 Mln Yuan
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT AGREES TO BUY 28 PERCENT STAKE IN MEDICAL EQUIPMENT FIRM FOR 406 MILLION YUAN ($62.73 million).  Full Article

Shanghai Fosun Pharmaceutical Group Enters Into JV Contract
Monday, 14 May 2018 

May 14 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::CO, WANBANG CLOUD HEALTH, SFHIH AND HAITUN INTERNATIONAL ENTERED INTO JV CONTRACT.JV CONTRACT IN RELATION TO ESTABLISHMENT OF JV COMPANY WITH A REGISTERED CAPITAL OF RMB18 MILLION.CO PROPOSED TO MAKE CASH CONTRIBUTION OF RMB4.5 MILLION, REPRESENTING 25% OF STAKE IN JV CO.  Full Article

Shanghai Fosun Pharmaceutical Group unit receives GMP certificate
Wednesday, 9 May 2018 

May 9 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says its pharmaceutical institute unit received goods manufacture practice (GMP) certificate from Chongqing Food and Drug Administration .Certificate issued to iron sucrose manufactured by the unit and the valid period is until April 19, 2023 .  Full Article

Shanghai Fosun Pharmaceutical Group to pay cash dividend of 3.8 yuan (pre-tax) for every 10 shares
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Says it plans to pay a cash dividend of 3.8 yuan (pre-tax) for every 10 shares as the dividend payment plan for 2017.  Full Article

Shanghai Fosun Pharmaceutical's 2017 Net Profit Up, To Invest Up To 1 Bln Yuan In Project
Monday, 26 Mar 2018 

March 26 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS 2017 NET PROFIT UP 11.4 PERCENT Y/Y.SAYS IT PLANS TO INVEST UP TO 1.03 BILLION YUAN IN MEDICINE PRODUCTION, INDUSTRIAL CENTRE PROJECT.  Full Article

Factbox - Who are Hong Kong's top biotech IPO hopefuls?

HONG KONG Biotechs without revenue can apply to list in Hong Kong from Monday under new rules aimed at attracting listings, mostly from China's fast-developing market.